Značaj cistatina C i kreatinina u dijagnostici akutnog oštećenja bubrega izazvanog kontrastom

  • Dejan Pilčević Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Nemanja Rančić Military Medical Academy, Centre for Clinical Pharmacology, Belgrade, Serbia
  • Zoran Jović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Violeta Rabrenović Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Svetlana Antić Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Marijana Petrović Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
  • Dejan Petrović Clinical Centre of Kragujevac, Clinic for Urology, Nephrology and Dialysis, Kragujevac, Serbia
  • Djoko Maksić Military Medical Academy, Clinic for Nephrology, Belgrade, Serbia
Ključne reči: bubreg, akutna insuficijencija, bubreg, hronična insuficijencija, angiografija koronarnih arterija, kreatinin, cistatin c

Sažetak


Uvod/Cilj. Kontrastom izazvano akutno oštećenje bubrega (KI-AOB) uobičajena je komplikacija nakon perkutane koronarne intervencije i dovodi do produžene hospitalizacije, povećanih medicinskih troškova i rizika od neželjenih kliničkih ishoda. Cilj rada bio je da se uporede promene u nivou serumskog kreatinina (sKr) i cistatina C (sCiC) 24 sata nakon učinjene koronarne angiografije kao ranih indikatora KI-ABO. Metode. Studija je obuhvatila 45 bolesnika sa hroničnom bubrežnom insuficijencijom 1–3. stadijuma kojima je planirana koronarna angiografija. Nivoi sKr i sCiC su mereni dan pre, kao i 24 sata posle koronarne angiografije. KI-ABO je bilo definisano kao povećanje nivoa sKr i sCiC od 25%, odnosno 10% u odnosu na bazalni nivo u roku od 24 sata nakon izlaganja kontrastnom sredstvu, a u odsustvu drugih alternativnih uzroka. Rezultati. Srednje vrednosti nivoa sKr i sCiC iznosile su 86,4 ± 22,6 µmoL/L i 1,18 ± 0,52 mg/dL, redom, pre primene kontrasta, odnosno 90,6 ± 24,1 µmoL/L i 1,24 ± 0,65 mg/dL, 24 sata nakon izlaganja kontrastnom sredstvu. S obzirom na nivo sKr, KI-ABO evidentirano je kod 4 bolesnika (8,89%), a s obzirom na nivo sCiC kod 19 bolesnika (42,22%) (p < 0,001). Zaključak. Nivo sCiC je osetljiviji indikator KI-ABO od sKr 24 sata nakon izlaganja kontrastnim sredstvima.

Reference

Aubry P, Brillet G, Catella L, Schmidt A, Bénard S. Outcomes, risk factors and health burden of contrast-induced acute kid-ney injury: an observational study of one million hospitaliza-tions with image-guided cardiovascular procedures. BMC Nephrol 2016; 17: 167.

Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv 2014; 7(1): 1–9.

Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficien-cy. Am J Kidney Dis 2002; 39(5): 930‒6.

Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast Media Safety Committee of Euro-pean Society of Urogenital Radiology (ESUR) Contrast in-duced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011; 21(12): 2527–41.

Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. In-cidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol 2014; 9(1): 12–20.

Kellum JA, Lameire, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global out-comes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kindey Int Suppl 2012; 2(1): 1‒138.

Solomon R, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. The CARE (Cardiac Angiography in Renally Impaired Patients) Study: A randomized, double-blind trial of contrast-induced nephropathy in high risk patients. Circula-tion 2007; 115(25): 3189‒96.

Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, et al. Nephrotoxic effects in highrisk patients undergoing angiography. N Engl J Med 2003; 348(6): 491‒9.

Morcos SK, Thomsen HS. European Society of Urogenital Radi-ology. European Society of Urogenital Radiology guidelines on administering contrast media. Abdom Imaging 2003; 28(2): 187–90.

McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103(5): 368‒75.

Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic con-trast media in 1196 patients: a randomized trial: the Iohexol Cooperative Study. Kidney Int 1995; 47(1): 254‒61.

Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: Physiological principles. Intensive Care Med 2004; 30(1): 33‒7.

American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005; 16(7): 1886‒903.

Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004 Aug; 8(4): R204-12.

Wasung ME, Chawla LS, Madero M. Biomarkers of renal func-tion, which and when? Clin Chim Acta 2015; 438: 350–7.

Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40: 1921‒6.

Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem 2015; 68: 57–69.

Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and contrast-induced acute kidney injury. Circulation 2010; 121(19): 2117–22.

Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, et al. Time course of serial cystatin C levels in com-parison with serum creatinine after application of radiocon-trast media. Clin Nephrol 2004; 61(2): 98‒102.

Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, et al. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012; 58(2): 458–64.

Xu Q, Wang N, Duan S, Liu N, Lei R, Cheng W, Zhou SK. Se-rum cystatin c is not superior to serum creatinine for early di-agnosis of contrast-induced nephropathy in patients who un-derwent angiography. J Clin Lab Anal 2017; 31(5): doi: 10.1002/jcla.22096.

National Kidney Foundation. K/DOQI clinical practice guide-lines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1‒266.

Kim GS, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Ele-vated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in pa-tients with peripheral artery disease undergoing endovascular therapy. J Vasc Surg 2015; 61(5): 1223‒30.

Dalton RN. Serum creatinine and glomerular filtration rate: Perception and reality. Clin Chem 2010; 56(5): 687‒9.

Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR – history, indica-tion and future research. Clin Biochem 2005; 38: 1‒8.

Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, et al. Association between increases in urinary neutrophil gelati-nase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105(3): 485‒91.

Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, et al. Time course of serial cystatin C levels in com-parison with serum creatinine after application of radiocon-trast media. Clin Nephrol 2004; 61(2): 98‒102.

Bellomo R. Decade in review – acute kidney injury: acute kid-ney injury - a decade of progress. Nat Rev Nephrol 2015; 11(11): 636–7.

Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H, et al. Ef-fect of N-acetylcysteine on cystatin C-based renal function af-ter elective coronary angiography (ENABLE Study): a pro-spective, randomized trial. Int J Cardiol 2010; 138(3): 239–45.

Feng Y, Zhang Y, Li G, Wang L. Relationship of cystatin-C change and the prevalence of death or dialysis need after acute kidney injury: a meta-analysis. Nephrology (Carlton) 2014; 19(11): 679–84.

Yin L, Li G, Liu T, Yuan R, Zheng X, Xu G, Xu Y et al. Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angi-oplasty: a randomized, controlled trial. Int J Cardiol 2013; 167(2): 426–9.

Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and contrast-induced acute kidney injury. Circulation 2010; 121(19): 2117‒22.

Zhang WF, Zhang T, Ding D, Sun SQ, Wang XL, Chu SC, et al. Use of Both Serum Cystatin C and Creatinine as Diagnostic Criteria for Contrast-Induced Acute Kidney Injury and Its Clinical Implications. J Am Heart Assoc 2017; 6(1): pii: e004747.

Liu XL, Wang ZJ, Yang Q, Yu M, Shen H, Nie B, et al. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention. Chin Med J (Engl) 2012; 125(6): 1051‒6.

Ribichini F, Gambaro G, Graziani MS, Pighi M, Peasrini G, Paso-li P, et al. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012; 58(2): 458‒64.

Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105(19): 2259‒64.

Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of con-trast-induced nephropathy after percutaneous coronary inter-vention. J Invasive Cardiol 2003; 15(1): 18‒22.

Davidson CJ, Hlatky M, Morris KG, Pieper K, Skelton TN, Schwab SJ, et al. Cardiovascular and renal toxicity of a nonionic radi-ographic contrast agent after cardiac catheterization: a pro-spective trial. Ann Intern Med 1989; 110(2): 119‒24.

Hall KA, Wong RW, Hunter GC, Camazine BM, Rappaport WA, Smyth SH, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res 1992; 53(4): 317‒20.

Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal func-tion deterioration within 48 h of interventional coronary pro-cedures in patients with pre-existent chronic renal insufficien-cy. J Am Coll Cardiol 2000; 36(5): 1542‒8.

Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79(2): 211‒9.

Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast‐induced nephropathy: a systematic review and me-ta‐analysis. Am J Nephrol 2011; 33(4): 344–51.

Gupta R, Moza A, Cooper CJ. Intravenous hydration and con-trast‐induced acute kidney injury: too much of a good thing? J Am Heart Assoc 2016; 5(6). pii: e003777.

Objavljeno
2021/04/02
Rubrika
Originalni članak